By Bhanvi Satija and Puyaan Singh (Reuters) - The U.S. Food and Drug Administration on Tuesday declined full approval for ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...

The Food and Drug Administration certainly gives little margarine for error after recalling nearly 80,000 pounds of Costco ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Greetings, and welcome to the Achieve Life Sciences Third Quarter ...

A Charleston woman was always short of breath and suffered from an undertreated heart problem. A new device at MUSC has her ...

Autolus Therapuetics plc has been granted FDA approval for Aucatzyl (obecabtagene autoleucel ... not have a risk evaluation and mitigation strategy attached to its label. The approval of Aucatzyl was ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.